MDxK

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein 2020-07-27 10:19:59
미국 Vanderbilt 백신센터 연구팀은 최근 Berkeley Light의 Beacon optofluidic system과 PacBio Sequel을 적용하여 SARS-CoV-2 스파이크 단백질에 대한 mAb 패널을 확인한 결과를 Nature Medicine에 발표하였습니다. 향상된 antibody discovery platform의 속도와 파워를 확인하실 수 있습니다. Abstract : Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms. PacBio 홈페이지에 Long Read SMRT sequencing을 COVID-19 과 SARS-CoV-2 연구에 어떻게 활용하실 수 있는지를 자세하게 살펴보실 수 있는 페이지가 개설되었습니다. Two main application areas. Sequencing SARS-CoV-2 genome Characterizing immune repertoire Tags #PacBio # multiomics # NGS # webinar
이전 Telomere-to telomre assambely .. Bionano detects a tandem ampli.. 다음

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

2020-07-27 10:19:59

미국 Vanderbilt 백신센터 연구팀은 최근 Berkeley Light의 Beacon optofluidic system과 PacBio Sequel을 적용하여 SARS-CoV-2 스파이크 단백질에 대한 mAb 패널을 확인한 결과를 Nature Medicine에 발표하였습니다. 향상된 antibody discovery platform의 속도와 파워를 확인하실 수 있습니다.

Abstract : Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.